BiotechTube
Gliknik

Gliknik

Baltimore, United States· Est.
gliknik.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

Founded in 2006, Gliknik is a private, pre-revenue biotech advancing a pipeline of proprietary recombinant Fc fusion proteins targeting autoimmune diseases and cancers. Its lead assets, GL-2045 and GL-0719, are both in clinical trials with patient dosing underway, aiming to address large markets with significant unmet needs. The company leverages expertise in immune system modulation and retains full ownership of its key programs, positioning it to capture significant value if successful. Leadership includes experienced industry veterans and scientific advisors with a track record in drug development.

Autoimmune DiseasesOncology

Technology Platform

Design and development of recombinant Fc fusion proteins for precise modulation of the immune system.

Funding History

4
Total raised:$85M
Series D$25M
Series C$30M
Series B$20M
Series A$10M

Opportunities

GL-2045 targets the ~$9B IVIG market with a potential subcutaneous, more potent alternative that could alleviate chronic supply shortages.
GL-0719's selective complement inhibition offers a differentiated approach in a growing therapeutic area with blockbuster potential, starting with rare diseases like Cold Agglutinin Disease.

Risk Factors

High clinical risk as programs transition from healthy volunteers to patient efficacy trials.
Financial risk as a private, pre-revenue company needing significant capital for late-stage development.
Competitive risk in crowded autoimmune and complement inhibitor markets.

Competitive Landscape

GL-2045 competes with IVIG products and other IVIG-replacement therapies in development. GL-0719 enters the competitive complement inhibitor space dominated by Alexion/AstraZeneca (Soliris, Ultomiris) and others, though its selective mechanism may offer a differentiation. Both programs face competition from large pharma and biotech firms with substantial resources.

More companies in Biologics / Biosimilars →More companies in United States →